AstraZeneca Sees Stock Market Value Slump by More than £20bn After Drug Setback
The failed trial in 1,432 patients sent AstraZeneca shares down as much as 11% and erased more than $20 billion in market value, Reuters reported.
- AstraZeneca's stock slumped 11% on Thursday, wiping out more than £20 billion in market value, after its heart disease drug Wainua failed to meet its primary trial goal.
- The CARDIO-TTRansform late-stage trial tested Wainua in 1,432 patients over 140 weeks to treat ATTR-CM, a heart condition affecting an estimated 300,000 to 500,000 people worldwide.
- Sharon Barr, AstraZeneca's executive vice president of biopharmaceuticals R&D, noted that for 57% of participants on stabilizer therapy, "Wainua had no effect," though a standalone subgroup showed "nominally significant" benefit.
- The failure dims a projected $2 billion peak-sales opportunity and threatens AstraZeneca's ambitious 2030 revenue targets, with analyst Chris Beauchamp calling it "a major blow for AstraZeneca."
- Wainua remains approved in more than 20 countries for polyneuropathy, earning $212 million in 2025 revenue, and Saxo strategist Neil Wilson emphasized the firm retains "many more irons in the fire.
28 Articles
28 Articles
The shares of the Swedish-British pharmaceutical company Astrazeneca were sinking in the London Stock Exchange more than 8% during the day. This, after the laboratory reported on the results of a study on Wainua, the company's titles were at 130.36 pounds sterling, despite closing at 142.40 ... Continue reading "Astrazeneca collapses in the Stock Exchange: presented drug for the heart that did not meet expectations" The post Astrazeneca collapse…
AstraZeneca Shares Sink After Heart Drug Trial Miss. Rare Clinical Setback Tests Investor Confidence
AstraZeneca shares fell sharply Thursday after the pharmaceutical giant reported that its experimental use of Wainua failed to achieve the primary endpoint in a late-stage clinical trial for a rare heart disease.
Wainua failed to meet her primary goal in an advanced phase study for a rare heart condition.
Coverage Details
Bias Distribution
- 54% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
